OSI Pharmaceuticals Announces Consolidation of U.S. Operations

OSI Pharmaceuticals Announces Consolidation of U.S. Operations

- Consolidation of Four Sites into a Single Campus Will Deliver Significant Operating Synergies Starting in 2010 and Allows for All Foreseeable Expansion Needs -

MELVILLE, N.Y., Jul 07, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today plans to consolidate its U.S. operations onto a single campus located in Ardsley, a community located in the town of Greenburgh in Westchester County, New York. The Company has signed an agreement to purchase a 43 acre site, which consists of ~400,000 sq.ft. of existing office and laboratory space for $27 million. Additional capital and one time expenses will be incurred, mainly during the latter part of 2009 and first half of 2010.

The Company announced that it expects to realize in excess of $15 million in yearly operating synergies upon completion of the consolidation, which is anticipated by the fourth quarter of 2010.

"The past ten years has been a remarkable journey as the Company has successfully brought its first oncology product, Tarceva(R), to market and taken the business profitable," stated Colin Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals. "None-the-less, we have recognized that we will only truly capture the full strategic value of our oncology franchise if we simplify our business by bringing together all the elements of our U.S. operations onto a single site. After an extensive and highly competitive process involving the exploration of options in multiple different states, we have identified a campus that will represent a first-rate facility for our company and provide for all foreseeable expansion needs over the next several years. We are delighted that OSI will remain in New York State and we look forward to being an integral part of a growing cluster of quality biotech companies in Westchester County."

The Company anticipates initiating the consolidation of approximately 350 current U.S. employees from its facilities in Melville and Farmingdale, NY, Boulder, CO, and Cedar Knolls, NJ in the second half of this year. OSI will receive incentives from New York State in connection with this move, with further potential incentives as the business continues to grow over the next five years. OSI will continue to operate its diabetes/obesity franchise in Oxford, England.

About OSI Pharmaceuticals

OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity. For additional information about OSI, please visit http://www.osip.com.

This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.Factors that might cause such a difference include, among others, OSI's and its collaborators' abilities to effectively market and sell Tarceva and to expand the approved indications for Tarceva, OSI's ability to protect its intellectual property rights, safety concerns regarding Tarceva,competition to Tarceva and OSI's drug candidatesfrom other biotechnology andpharmaceutical companies, the completion of clinical trials, the effects of FDA and other governmental regulation, including pricing controls,OSI's ability to successfully develop and commercialize drug candidates, and other factors described in OSI Pharmaceuticals' filings with the Securities and Exchange Commission.

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.